Rationale: Despite increasing prevalence and incidence of heart failure (HF), therapeutic options remain limited. In early stages of HF, sudden cardiac death (SCD) from ventricular arrhythmias claims many lives. Reactive oxygen species (ROS) have been implicated in both arrhythmias and contractile dysfunction. However, little is known about how ROS in specific subcellular compartments contribute to HF or SCD pathophysiology. The role of ROS in chronic proteome remodeling has not been explored.
H eart failure (HF) is a clinical syndrome of progressive functional degradation that occurs secondary to various insults including hypertension, myocardial infarction, tachycardia, or toxic stimuli. It affects an estimated 26 million people worldwide 1 and in the United States alone, there are ≈300 000 HF-related deaths per year with an estimated economic impact of $39 billion. 2 Although conventional treatments forestall cardiac pump failure, 2% to 5% of HF patients still die of sudden cardiac death (SCD) each year. 3 There are few effective treatments to prevent SCD, although implantable cardioverter-defibrillators can decrease fatalities from such events. However, many HF patients die before meeting the criteria for implantable cardioverter-defibrillator implantation (cardiac ejection fraction <35%), and in a community-wide study, only one third of SCD cases analyzed had left ventricular dysfunction severe enough to qualify for a prophylactic implantable cardioverter-defibrillator. 4 Moreover, in a more selective group of patients with nonischemic systolic HF, implantable cardioverter-defibrillator therapy decreased SCD but did not significantly improve long-term survival. 5 Thus, novel therapies for HF/SCD are urgently needed.
functions has been noted in HF, including defects in network organization, fission/fusion, mitophagy, biogenesis, substrate selection, oxidative phosphorylation, the unfolded protein response, and redox signaling. Defective mitochondrial reactive oxygen species (mROS) handling has emerged as a central factor, 10 underscored by data in transgenic mice showing that overexpression of an ROS-scavenging enzyme (catalase) in the mitochondria, but not the cytoplasm, blunts HF. 11 The need to target a specific source of ROS, in a specific compartment, may partly explain why clinical trials of more general antioxidants, such as vitamins E 12 or C, 13 have failed to improve, or even worsened, outcomes in HF patients. Targeting mitochondrial oxidative stress with a peptide (eg, elamipretide) that prevents cardiolipin oxidation 14 improves outcomes in animal models of ischemia-reperfusion injury 15 or pressure-overload HF, 16 but it is still unclear whether it is effective in humans. [17] [18] [19] The clinical effectiveness of MitoQ, a targeted form of ubiquinone, in HF also remains to be determined. 20 It is unknown if mitochondrial antioxidant therapy is beneficial for HF-associated SCD, in part, because of a paucity of appropriate animal models. In this regard, we previously reported that preserving mitochondrial ROS balance by enhancing coupling between Ca 2+ and the Krebs cycle abrogated oxidative stress during increased energy demand and prevented both SCD and HF progression in a guinea pig model of acquired long QT and spontaneous SCD, which has electrophysiological and Ca 2+ handling characteristics close to that of humans. 8 All of these studies provide a strong rationale for targeting mROS to prevent both acute adverse events and chronic remodeling in HF; however, it is not known what mechanisms are involved in coupling mROS to HF signaling, or whether mitochondrial antioxidant intervention has the potential to rescue cardiac function and prevent SCD when HF is already present. Moreover, how mROS intervention impacts the signal transduction pathways and protein post-translational modifications implicated in cardiac hypertrophy and failure has not been determined.
Here, we establish mROS as the key driver of HF remodeling and SCD from the subcellular level to the whole organism by using novel tools to assess: (1) compartment-specific ROS responses in ventricular myocytes from normal and failing hearts, (2) the ability of a targeted mROS scavenger to prevent or reverse HF and SCD in vivo, and (3) 
Novelty and Significance
What Is Known?
• Sudden cardiac death (SCD) from ventricular arrhythmias accounts for the majority of deaths in the early stages of heart failure (HF).
• The mechanisms of SCD are poorly understood, precluding the development of new, more effective therapies.
• Reactive oxygen species (ROS), sources of oxidative stress, have been implicated in the pathogenesis of both HF and SCD, but little is known about the role of compartment-specific ROS dynamics.
• The response to antioxidant therapies in clinical trials has been mixed at best, but the effect of targeted compartment-specific antioxidant therapy remains to be established.
What New Information Does This Article Contribute?
• We quantified compartment-specific ROS dynamics and elucidated the acute and chronic roles of mitochondrial ROS (mROS) in the context of HF, ventricular arrhythmias, and SCD, in a guinea pig model that uniquely recapitulates key features of human HF, including acquired long QT, progression from hypertrophic to dilated cardiomyopathy, and a high incidence of spontaneous SCD.
• In vivo scavenging of mROS not only prevented the progression of HF and eliminated SCD, but also reversed the impaired contractility of failing hearts.
• The beneficial effects of mROS scavenging include prevention of HF-associated chronic proteome and phosphoproteome remodeling through mitigation of ROS-sensitive signaling pathways.
Although HF confers a higher risk for SCD, the mechanisms linking HF and SCD remain unclear. Understanding the mechanisms is essential for improved identification of individuals at high risk for SCD and for the design of new, more effective therapies. Implantable cardioverter-defibrillators are the only effective therapy for SCD, but this is palliative and carries many risks. Importantly, implantable cardioverter-defibrillators do not prevent or reverse the disease process. Multiple sources of ROS in specific subcellular compartments may contribute to HF, but these have not been selectively quantified before. Herein, we show that impaired mROS balance is the major contributor to high basal and demand-stimulated ROS levels in HF, with NADPH oxidase contributing to cytoplasmic ROS primarily during angiotensin II receptor stimulation. Enhancing mROS scavenging with a targeted superoxide scavenger prevents and reverses electrical instability, contractile failure and chronic HF-induced proteome/phosphoproteome remodeling, and prevents SCD. Our results support the feasibility of targeting the mitochondria for therapeutic intervention in HF and SCD while identifying new mROS-sensitive protein modifications.
of mitochondrial antioxidant intervention on changes in the proteome and phosphoproteome that occur during the development of HF. We show, for the first time, that baseline and stimulated H 2 O 2 levels are elevated in the mitochondrial matrix compartment in HF and that SCD can be eliminated and contractile function rescued by an mROS scavenger. We describe the HF-induced changes in the proteome and phosphoproteome that are mROS dependent, opening the door to novel protein targets and pathways for therapeutic intervention for HF/SCD.
Methods
All data and materials supporting the findings of this study are available within the article and in the Online Data Supplement or from the corresponding authors on reasonable request.
Results

Spontaneous Nonfatal (Premature Ventricular Complex) and Fatal (SCD) Arrhythmia Incidence During Cardiac Hypertrophy and Failure
The guinea pig HF/SCD model combines ascending aortic constriction (AC) with once daily administration of the β-adrenergic agonist, isoproterenol (2 mg kg
, and progresses from a brief compensated hypertrophy phase (<2 weeks postbanding) to HF by 4 weeks post-banding. 8 The model displays typical hallmarks of HF, including prolonged QT interval, cellular action potential prolongation, downregulation of repolarizing K + channels (eg, KCNJ2, KCNH4, KCNQ1), depressed Ca 2+ handling proteins (CACNA1C, ATP2A2, RYR2), and decreases in mitochondrial metabolic and antioxidant proteins. 21 Pathways of inflammation and extracellular matrix remodeling are also markedly increased in this model. 21 A unique feature of the model is the high incidence of spontaneous SCD (≈60% over 4 weeks) because of ventricular tachycardia/ventricular fibrillation ( Figure 1A ), usually occurring in the recovery periods in between the daily β-adrenergic challenge delivered by an implanted programmable pump. Although QT prolongation ( Figure 1B ) and SCD occurs quite early after pressure overload, before overt failure, the rate of nonfatal premature ventricular complexes increased over time, in parallel with the cardiac contractile decompensation ( Figure 1C Possible sources of ROS contributing to oxidative stress in HF include the mitochondrial electron transport chain, NADPH oxidases, monoamine oxidases, xanthine oxidase, or uncoupled nitric oxide synthase 24 ( Figure 2B ). Crosstalk between compartments can occur in several ways: (1) by mitochondrial ROS-induced ROS release, 25 whereby cytoplasmic ROS (cROS) is amplified by a regenerative mitochondrial ROS response; (2) by mitochondrial ROS-dependent activation of NADPH oxidase 26 ; or (3) by the scavenger system of 1 compartment (eg, the mitochondria) contributing to ROS scavenging in another, 27 given the membrane permeability of H 2 O 2 . Measurement of baseline ROS levels in mitochondria (mROS) and cytoplasm (cROS) of quiescent left ventricular myocytes from normal and failing hearts ( Figure 2C ) revealed that H 2 O 2 (expressed as F ox ) in the failing group was significantly higher in both compartments compared with normal nonfailing heart cells (cROS Normal: 0.26±0.01; cROS HF: 0.47±0.02; P<0.05; mROS Normal: 0.29±0.020; mROS HF: 0.57±0.02; P<0.05). The dynamic response to a fixed ROS exposure (1 mmol/L tert-butyl hydroperoxide) was tested, and markedly higher H 2 O 2 levels were observed in HF myocytes compared with normal, in both the cytoplasm and mitochondrial matrix compartments under exogenous ROS stress ( Figure 2D ). These findings are consistent with the significant downregulation of mitochondrial antioxidant proteins in this model 21 (and in the proteomics data described below). We previously demonstrated that increased work by electrical stimulation in the presence of β-adrenergic activation greatly enhances ROS accumulation measured with an untargeted ROS probe (carboxymethyl dihydrodichlorofluorescein) in HF/SCD myocytes. 8 Interestingly, using the targeted probes, here we show that mROS increased significantly during 1 Hz pacing in the ACi group, but only in the presence of β-adrenergic stimulation ( Figure 2E )-when the order was reversed, we discovered that β-adrenergic stimulation alone sufficed to induce near maximal mitochondrial oxidative stress ( Figure 2F ). This effect was not reversed by uncoupling contraction from excitation/Ca 2+ using blebbistatin ( Figure 2G ). Indeed, in the presence of blebbistatin, pacing without β-adrenergic activation lowered mROS in HF/SCD cells down to the normal levels, presumably by increasing NADPH availability through Ca 2+ -stimulated activation of the Krebs cycle. 8, 28 This effect on mROS was overcome when a higher energy demand (through increased Ca 2+ cycling) was imposed by β-adrenergic receptor activation. The cROS responses for the same protocols described above showed an additive effect of isoproterenol and pacing ( Figure 2J and 2K), as well as suppression of the cROS response by blebbistatin treatment with no anomalous effects ( Figure 2L ). MitoTEMPO is composed of a heterocyclic nitroxyl moiety linked to a triphenylphosphonium ion that facilitates its accumulation in mitochondria, 29 conferring functionality as a superoxide dismutase mimetic and peroxyl scavenger. MitoTEMPO attenuated both mROS and cROS generation in the presence of β-adrenergic stimulation with pacing ( Figure 2H and 2M). The untargeted antioxidant analog Tempol, however, did not prevent mROS generation in the presence of β-adrenergic stimulation ( Figure 2I ). These observations indicate that the mROS response to both energy demand and β-adrenergic stimulation are enhanced in HF.
We next evaluated the impact of mitochondrial versus nonmitochondrial ROS sources on compartment-specific redox responses. MitoTEMPO (25 nmol/L) effectively normalized both cROS and mROS in ACi myocytes, while minimally impacting ROS in Normal control myocytes. Tempol also normalized both mROS and cROS in ACi myocytes at baseline, but, as described above, was less effective than MitoTEMPO under conditions of high oxidative stress. In contrast, the NOX (NADPH oxidase) inhibitor apocynin (100 µmol/L) only partially inhibited cROS and decreased mROS marginally in ACi myocytes ( Figure 3A and 3B). GP91-ds-tat (3 µmol/L), a specific inhibitor of NOX2, similarly had a marginal effect on mROS and cROS in myocytes from failing hearts. These data indicate that basal, receptor independent, NOX activity, in the absence of exogenous Ang II (angiotensin II), contributes to oxidative stress in HF myocytes, but to a lesser extent than do mitochondria. Moreover, mitochondria are essential for scavenging ROS in both the mitochondrial matrix and the cytosol compartments.
Compartment-Specific ROS Responses to Ang II Receptor Activation
Activation of the renin-angiotensin system leads to elevated Ang II in HF and contributes to left ventricular structural remodeling. Ang II receptor-mediated NOX activation triggers ROS-dependent signal cascades that contribute to cardiac Figure 2 Continued. myocytes (blue bars). E, In a sequential protocol, pacing alone (1 Hz) did not significantly increase mROS in either normal controls or ACi myocytes unless paired with β-AR stimulation with isoproterenol (Iso; 100 nmol/L). F, In a second protocol, Iso, given first, increased intracellular mROS production without pacing in the ACi group. Baseline and stimulated mROS levels were higher in ACi compared with the normal group. G, Uncoupling myofilament activation from EC coupling with blebbistatin treatment prevented the mROS increase from field stimulation alone (the level was even decreased), but did not suppress mROS accumulation induced by Iso+Pacing in ACi myocytes. H, Treatment with MitoTEMPO (MT) inhibited ROS generation in the presence of Iso+Pacing. On the contrary, Tempol (I) was not able to prevent ROS generation. cROS response for sequential application of Pacing (1 Hz)+Iso (J) or Iso+Pacing (K) in normal or ACi groups. cROS was maximally elevated in both groups when Pacing and Iso were combined, whereas Blebbistatin (L) markedly suppressed the exaggerated cROS response in ACi. M, MT also effectively inhibited cROS generation in presence of Iso+Pacing. N≥5 replicates for all experiments, >20 myocytes for each group; Error bars show SEM; *P<0.05 vs control group. RIRR indicates ROS-induced ROS release.
hypertrophy and fibrosis and NOX-derived ROS might also directly impact excitation-contraction coupling and increase arrhythmias through redox effects on Ca 2+ handling proteins and ion channels. 30 To date, Ang II hormone-stimulated H 2 O 2 responses in the cytoplasmic and mitochondrial compartments have not been selectively measured in cardiac myocytes. Therefore, we examined the H 2 O 2 response to Ang II (100 pmol/L), and its inhibition by the antagonist losartan (100 nmol/L), in normal and HF myocytes in the cytoplasm (cytoORP) and in the mitochondrial matrix (mitoORP), where the NOX signal could propagate through ROS-induced ROS release. 9 Ang II significantly increased both mROS ( Figure 3C ) and cROS ( Figure 3H ) in HF and Normal groups (P<0.05), and this effect was inhibited by Ang II receptor blockade with losartan (P<0.01). Notably, the absolute increase in ROS level attributable to Ang II stimulation was similar in normal and HF groups, although the latter took place on top of the higher baseline noted above. In addition, unlike apocynin, losartan had no effect on basal ROS, indicating that the high baseline was not because of auto activation of Ang II receptors by endogenous Ang II, known to be present in heart cells, 31 but rather, was mediated by a constitutively active, yet undetermined, ROS source. Tempol normalized baseline mROS and cROS in ACi (P<0.01), but only partially blocked mROS generation in the presence of Ang II (mROS versus cROS, P<0.05; Figure 3D and 3I). This partial suppression could reflect the contribution of ROS-induced ROS release to mitochondrial oxidative stress during Ang II Figure 3 . Targeted antioxidant effects on mitochondrial reactive oxygen species (mROS) and cytoplasmic ROS (cROS) in heart failure (HF). A, B, MitoTEMPO (MT), the mROS-specific scavenger, markedly decreased basal mROS (A) and cROS (B) in left ventricular (LV) myocytes from ACi hearts and partly (not significant) suppressed basal mROS in normal myocytes. Tempol, a general antioxidant, decreased mROS and cROS Apocynin, an NOX (NADPH oxidase) inhibitor and GP91-ds-tat (peptide inhibitor for NOX2), decreased cROS in both normal and ACi significantly, but had only a modest (but significant) effect on mROS in ACi. Both apocynin and GP91-ds-tat had no effect on mROS levels in the Normal group. C, Ang II (angiotensin II) increased mROS in both normal and ACi groups. Reversal by the Angiotensin receptor blocker Losartan (Los) confirmed that effects are mediated by the Angiotensin type 1 receptor. High baseline levels contributed to higher overall ROS levels in ACi, but the Ang II-activated/Los-sensitive mROS responses were quantitatively similar in normal and ACi groups. Los did not decrease the high baseline ROS levels in ACi. D, I, Treatment with Tempol blunted Ang II responses in both mROS and cROS, compared to the respective control responses (C, H). E, F, J, K, Treatment with Apocynin and GP91-ds-tat only marginally changed the Ang II-induced ROS in the mitochondrial compartment, but basal and Ang II-stimulated cROS were sensitive to Apocynin and GP91-ds-tat. G, L, MT lowered the baseline ROS levels and effectively prevented Ang II-mediated increase in mROS but did not abolish cROS generation on Ang II stimulation; N≥5 replicates for all experiments, >20 myocytes for each group; Error bars show SEM; *P<0.05 vs control group, ANOVA; P<0.001. receptor activation. Like Tempol, Apocynin had a greater effect on Ang II-induced cROS ( Figure 3K ) than mROS (mROS versus cROS, P<0.05; Figure 3F ) in addition to its baseline cROS-lowering effect.
Consistent with this, specifically targeting NOX2 inhibition with GP91-ds-tat only marginally alleviated mROS while significantly supressing cROS in the presence of Ang II (mROS versus cROS, P<0.01; Figure 3E and 3J). The effect of Ang II on cROS in the presence of GP91-ds-tat was modest but significant (P<0.01). Interestingly, in the presence of either the NOX2-specific inhibitor (GP91-dstat) or the nonselective oxidase inhibitor (apocynin), mROS generation was still not suppressed during Ang II activation, suggesting that an alternative pathway besides NOX2 was activated by receptor stimulation leading to mitochondrial oxidative stress. Most importantly, MitoTEMPO blocked the increase in mROS signal in the presence of Ang II (P<0.01; Figure 3G ) but did not suppress the cROS response ( Figure 3L ), demonstrating that it does preferentially scavenge mROS over extramitochondrial sources.
Mitochondrially Targeted Antioxidant Therapy Prevents or Reverses HF and SCD
The cellular data described above indicated that oxidative stress in HF/SCD myocytes could be normalized by MitoTEMPO. To determine if this intervention could be used therapeutically to mitigate HF or SCD in vivo, we designed a crossover study in which MitoTEMPO (delivered via implanted osmotic pump, dose: 0.7 mg kg −1 d When MitoTEMPO was present during the entire protocol, no mortality was observed ( Figure 4B ) and cardiac function did not decline over 4 weeks, similar to the normal controls ( Figure 4C ). Moreover, MitoTEMPO-treated animals showed no cardiac dilation (Online Figure IA) . Interestingly, in the ACiMT +/− group, although HF and SCD were prevented initially, cessation of MitoTEMPO treatment at 3-week post-banding resulted in a rapid descent into HF (decline in fractional shortening% from 46% to 31%; Figure 4C) . Surprisingly, removing supplemental mROS scavenging quickly led to HF, but did not increase SCD incidence ( Figure 4B ). Most important from the therapeutic perspective, the ACiMT −/+ group demonstrated that HF could be reversed, and SCD eliminated, by MitoTEMPO treatment after HF/SCD is already present ( Figure 4B ). Cardiac function improved (fractional shortening% from 30% to 42%; Figure 4C ) and 100% of the animals survived after the introduction of MitoTEMPO at week 3 ( Figure 4B ).
To extend the validity of our findings to a different HF model that was not subjected to daily isoproterenol stress, we repeated the MitoTEMPO treatment protocol in a guinea pig model of AC alone. 8 Observations were made over a period of 5 weeks. The AC group does not experience SCD and demonstrates a slow progression of HF over a period of 6 to 8 weeks. Death occurs at end stage because of pump failure. Whereas cardiac function in AC starts declining by week 2 post-banding, treatment with MitoTEMPO preserved the cardiac function and prevented the onset of HF (Online Figure IV) .
Effects of MitoTEMPO on In Vivo Electrophysiological Properties of HF/SCD Model
Analysis of the electrophysiological phenotype showed that MitoTEMPO had no effect on basal heart rate or the response to daily isoproterenol challenge (Online Figure  IB) . The daily isoproterenol infusion rapidly increased heart rate to a maximum of ≈390 to 400 bpm in all groups and then it slowly declined back to the baseline rate in ≈4 hours. Continuous telemetry recordings indicated a high frequency of premature ventricular complexes ( Figure 5A ) and spontaneous ventricular tachycardia/ventricular fibrillation in the ACi group ( Figure 1A) , as well as in the ACiMT −/+ group before initiating MitoTEMPO treatment. MitoTEMPO treatment markedly suppressed arrhythmias ( Figure 5A ) and blunted QT prolongation evident by 4 weeks post-banding ( Figure 5B ). The ACi and ACiMT −/+ groups (before treatment) demonstrated increased dispersion of repolarization, as indicated by a variable amplitude and duration of the T wave ( Figure 5C ), which is considered prognostic of arrhythmia risk and is frequently increased in patients with prolonged QT interval. MitoTEMPO treatment of the ACi animals reduced the dispersion of repolarization ( Figure 5D ), as indexed by the QT variability index, 32, 33 in parallel with the elimination of SCD.
MitoTEMPO Prevents HF Proteome and Phosphoproteome Remodeling
Next, we sought to define the impact of mitochondrial antioxidant therapy on (1) HF/SCD-associated proteome remodeling, (2) changes in the specific phosphorylation of proteins altered in HF, and (3) the signal transduction pathways underlying HF/SCD that were normalized by MitoTEMPO treatment. Hearts from Normal, ACi, or ACiMT groups were excised, and the left ventricular free wall was immediately subjected to rapid heat stabilization to halt biological activity (Denator AB, Sweden). This method has been shown to be superior to snap freezing for the preservation of phosphorylation-dependent post-translational modifications. 34 Proteins were extracted from the hearts and digested for labeling with Tandem Mass Tags ( Figure 6A ). Samples were then mixed and divided into unenriched and titanium dioxide (TiO 2 )-enriched fractions for multiplex LC-MS/MS analysis of the expression proteome and phosphoproteome, respectively. Spectral normalization and statistical methods were as described previously, 21 and principal components analysis, hierarchical clustering, pathway, and causal network analyses were performed using commercial software packages, as described in the Methods in the Online Data Supplement. Peptide identification/quantification, statistical and pathway analyses, and specific phosphosite annotations are available in Proteomics Data in the Online Data Supplement. The internal structure of the variance of the data, as illustrated by principal components analysis, for both the expression proteome ( Figure 6B ) and the phosphoproteome ( Figure 6C ), revealed that MitoTEMPO-treated ACi hearts resembled normal nonfailing hearts with respect to the largest principal component (PC1), whereas no groupwise distinction was evident in the second component (PC2). We detected 4195 phosphoforms (on 1550 proteins) and were able to quantify specific phosphorylation for 2951 phosphoforms (that is, we had corresponding expression data). As expected, there was an overall correlation between the change in phosphoform abundance and protein abundance in HF, but many individual phosphoforms changed more dramatically than the underlying protein ( Figure 6D ; colored yellow and blue, respectively). To extract bona fide differential phosphoform regulation between the Normal, ACi, and ACiMT groups, irrespective of changes in protein abundance, specific phosphorylation was calculated by subtracting the protein abundance from phosphoform abundance on the log2 scale (equivalent to dividing on the linear scale) for each of the samples. Once normalized, the specific phosphoproteome from ACi hearts remained distinct from that of Normal or ACiMT hearts with respect to PC1 ( Figure 6E) .
Heatmaps of hierarchically clustered upregulated or downregulated proteins in the proteome ( Figure 6F, P<0.05 ) and the specific phosphoproteome ( Figure 6K , P<0.05) illustrate how MitoTEMPO largely prevented HF-induced protein remodeling, as well as the post-translational modifications induced by the ACi protocol, in accord with the protective functional effects described above. Moreover, K-means cluster analysis identified 1680 proteins whose abundance increased or decreased in HF in the expression proteome that were prevented by MitoTEMPO ( Figure 6G ). Sixty-six percent (1115) of these reached statistical significance (P<0.05) by LIMMA multigroup test 35 (Venn diagram intersection in Figure 6H ). Similarly, 970 phosphoform changes altered in HF were prevented by MitoTEMPO treatment (Figure 6L and 6M) and 67% (648) of these reached significance (P<0.05 by LIMMA; Figure 6M ).
The HF protein changes prevented by MitoTEMPO (ie, those modulated by mROS) were subjected to pathway analysis (IPA, Qiagen). Significantly overrepresented pathways (Benjamini-Hochberg corrected P<0.05) are tabulated in Proteomics Data in the Online Data Supplement, with z scores indicating which pathways are inferred activated or inhibited in HF that were specifically responsive to mitochondrial antioxidant treatment. Top mROS-activated pathways in the HF expression proteome (orange bars in Figure 6I ) included Rho GTPase, integrin signaling, cytoskeletal remodeling, and ERK/MAPK signaling, whereas HF pathways inhibited by mROS prominently featured nuclear receptors regulating indicates that the experimental groups primarily segregate along the first principal component (PC No. 1), with the ACi group (red) the most distinct of the 3 proteomes, whereas the ACiMT (blue) and Normal (green) heart proteomes differed marginally from each other. C, PCA of the phosphoproteome. D, Plot of HF-induced changes in phosphoproteins as a function of their changes in expression level, when compared with normal controls, used to determine extent of hyper-or hypophosphorylation (colored according to the binned distribution of log 2 (∆phos/∆prot) HF ). E, After accounting for protein expression, ACi phosphoproteome was still distinct as assessed by PCA. F-I, Identification of biological pathways in HF influenced by MitoTEMPO, we examined subset of proteins whose levels differed significantly between groups and whose changes were mitigated by MitoTEMPO. F, A heatmap was used to visualize the supervised hierarchical correlation clustering of proteins with P<0.05 by LIMMA multigroup comparison. G, K-means clustering to parse the proteome by signal intensity into groups whose expression changed in ACi relative to the normal group, but were also mitigated by MitoTEMPO. H, Proteins meeting both criteria (the intersection of sets from F and G; 1115 proteins) were subjected to further Pathway Analysis. I, Ingenuity Pathway (Continued ) metabolic protein expression, that is, PPAR, RXR, and LXR, as well as the Rho GDP dissociation inhibitor pathway (blue bars in Figure 6I) .
We next performed a causal network analysis to identify master upstream regulators that might contribute directly, or through other regulators, to the HF phenotype that were specifically prevented by MitoTEMPO treatment. Validating this approach, hydrogen peroxide was identified as a putative regulator with a high positive z score, along with MAP kinases, angiotensin receptor, TGF (transforming growth factor)-β1, and NOX. The putative regulators inhibited in HF and prevented by MitoTEMPO included the negative regulator of MAP kinases, PTPRR (protein tyrosine phosphatase receptor type R), PPARα-RXRα, and DGKE (diacylglycerol kinases; Figure 6J ).
Pathway and upstream regulator analysis was also performed on the phosphoproteome data. In this case, activation or inhibition of activity cannot be predicted, as it would depend on the specific functional impact of hypo-or hyperphosphorylation on each individual target. Nevertheless, significant changes in phosphorylation state of proteins residing in PKA/β-adrenergic, RhoA signaling, PKG (Effects of Sildenafil), nitric oxide, integrin, angiotensin, TGF-β, and MAP kinase signaling pathways were observed ( Figure 6L through 6O ). Significant downregulation of mitochondrial antioxidant, tricarboxylic acid cycle, and electron transport chain proteins were observed in the ACi group that were abrogated by MitoTEMPO treatment (Online Figure II) . Of special relevance to the SCD phenotype, changes in the expression and phosphorylation profile of proteins essential for excitation-contraction coupling (ion channels and transporters) were in evidence (Online Figure III) .
Pathway analysis strongly implicated the 3 main MAP kinase pathways (ERK1/2, p38, and JNK) as upstream causal regulators of the gene networks altered in HF that were prevented by MitoTEMPO treatment. Direct evidence of changes in the mROS-sensitive expression of MAPK cascade proteins with HF was present in the proteome ( Figure 6P ). Further confirmation was obtained by kinome analysis (Cell Signaling, Inc) using an antibody recognizing canonical proline-directed (sequence proline-directed Ser phosphorylation) MAP kinase substrate phosphosites ( Figure 6Q ), indicating activation of MAPK target phosphorylation in the ACi model at end-stage HF (as well as in AC without concomitant isoproterenol treatment), with modest activation also observed at the compensated hypertrophy stage, when there are far fewer changes in protein expression.
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Discussion
The major finding of this study was that mROS scavenging can prevent the onset of HF, or reverse established HF, while eliminating SCD, although the former effect persisted only if the treatment was sustained. Mitochondrial ROS was shown to be a major contributor to chronic HF-induced protein remodeling, as demonstrated by the beneficial effects cardiac of MitoTEMPO on protein expression and post-translational modification (phosphoproteome). Importantly, this study is the first to characterize the global subset of protein phosphotargets implicated in HF that are mROS dependent. In addition, using novel compartment-specific ROS probes, it was shown that these effects were consistent with the ability of MitoTEMPO to normalize ROS levels in the mitochondrial matrix and cytosolic compartments of failing heart cells. Reversing the deficit of mROS scavenging in HF was sufficient to reverse the HF phenotype and prevent sudden death even though other apocynin-sensitive sources of ROS were present, contributing to elevated basal and Ang II-stimulated ROS in the cytoplasm. The observation that contractile function was preserved only as long as the exogenous scavenger was present indicates that cardiac decompensation is an mROS-dependent process. As MitoTEMPO was delivered as a systemic drug, extracardiac effects of MitoTEMPO cannot be discounted. But the agreement between the effects in myocytes and effects on cardiac physiology is consistent with the conclusions in this study. The ability of MitoTEMPO to impact the ventricular proteome and phosphoproteome, to decrease arrhythmia incidence and to restore contractility support cardiac muscle as a primary target.
Antioxidant therapy for HF has had a long, and somewhat disappointing, history. Various antioxidants have been shown to prevent hypertrophy and failure in animal models and attenuate cardiomyocyte growth in cell models of agonist-induced hypertrophy. For example, vitamin E or catalase treatment inhibited the hypertrophic response to TNF (tumor necrosis factor)-α or Ang II in neonatal rat cardiomyocytes 36 and chronic vitamin E treatment of blunted pressure-overload hypertrophy and HF in guinea pigs subjected to AC for 20 weeks. 37 In mice subjected to transverse AC, N-2-mercaptopropionylglycine treatment attenuated the increase in the HF biomarker atrial natriuretic peptide and slightly decreased cardiac hypertrophy without effects on hemodynamics, 38 whereas the superoxide dismutase mimetic, M40401, 39 or TEMPOL 40 attenuated markers of oxidative stress but did not prevent HF. Examples of positive effects of antioxidants on post-MI injury and coronary artery disease are also well represented in the literature, 41 Figure 6 Continued. Analysis of the proteins changed in ACi but mitigated by MitoTEMPO (Benjamini-Hochberg-corrected p values <0.05) were ranked by z score. Orange represents pathways inferred to be activated in ACi but not in ACiMT group and blue represents pathways inferred to be inhibited in ACi but not in ACiMT group. Cytoskeletal remodeling and MAP Kinase pathways exemplify the former and ligand-activated metabolic transcription factor pathways (ie, LXR/RXR, PPAR) exemplify the latter. J, Ranking of causal regulators (by z score, full list in the Online Data Supplement) associated with ACi but not changed in ACiMT group. These represent master regulators whose activation or inhibition is consistent with expression or activation states of other subordinate regulators within the data set. Note that hydrogen peroxide is an inferred primary regulator identified by the MitoTEMPO-influenced proteome. K-M, LIMMA and K-means clustering analysis for the specific Phosphoproteome. Six hundred forty-eight Phosphoforms met the aforementioned 2 criteria, corresponding to 334 phosphoproteins. N, Over-representation analysis of the phosphoproteins indicates they fall into pathways that include β-adrenergic signaling, integrin signaling, nitric oxide signaling, ERK/MAPK signaling and calcium signaling, among others (activation state undeterminable). O, Upstream regulators that impact the phosphoprotein levels irrespective of phosphorylation status. P, ACi-associated alterations in expression of MAP kinase pathway proteins that were prevented by MitoTEMPO treatment. Q, Increase in canonical (proline-directed) MAP kinase target phosphorylation sites in end-stage heart failure with aortic constriction (AC) alone or in the ACi model compared with nonfailing sham-operated controls (each lane is a sample from 5 to 6 pooled hearts per group). Right, Equivalence of sample loading by Coomassie blue staining.
with several small clinical trials showing beneficial outcomes in humans. 42, 43 Nevertheless, larger prospective clinical trials for several nutritional (Vitamin E and C 42, [44] [45] [46] [47] ) or general antioxidants (NAC, 48 oxypurinol 49 ) have either shown no benefit or detrimental outcomes. Speculation about the reasons for the failure to demonstrate efficacy in humans includes a failure of the antioxidant to reach sufficient levels in the appropriate compartment, insufficient ability of the tissues to regenerate the antioxidant after electron transfer, thus rendering it an oxidant, 50 or too much ROS scavenging suppressing physiological signals that may protect the heart. In an attempt to overcome one or more of these problems, the focus has recently shifted toward antioxidants targeted to the mitochondria. 20 This approach was spurred on by results in mouse models of hypertrophy 51 or cardiac aging 52 showing that transgenic overexpression of a mitochondrial, but not a cytoplasmic, catalase (an enzyme that scavenges H 2 O 2 ) prevented cardiac dysfunction. Interestingly, 6-fold cardiac-specific overexpression of mitochondrial superoxide dismutase in transgenic mice caused physiological hypertrophy and supranormal function, which was attributed to improved myocardial blood flow because of increased H 2 O 2 efflux into the vasculature. 53 Antioxidant molecules linked to a triphenylphosphonium ion (TPP + ), such as SkQ1, 49, 54, 55 mitoQ, 49 and MitoTEMPO, 49 facilitate partitioning of the antioxidant into the mitochondrial matrix compartment according to the Nernst potential of the lipophilic cation (in cardiac mitochondria, this would result more than a 3000-fold increase in the level of the compound in the matrix compared with the extracellular space). Lifelong treatment of mice with the targeted plastoquinone SkQ1 decreased age-related cardiac fibrosis and hypertrophy 55 with minimal effects on gene expression, although significant changes in gene pathways involved in cell-cell contact, leukocyte extravasation, and inflammation were noted. MitoQ10, a targeted form of coenzyme Q 49 , decreased systemic blood pressure and the associated cardiac hypertrophy in spontaneously hypertensive rats. 56 Long-term (28 weeks) treatment of normal mice with MitoQ also had minimal effects on metabolism or gene expression. 57 Although MitoQ treatment seems to be protective in many situations involving oxidative damage, such as ischemiareperfusion injury, 58 it is still unclear whether it is effective in preventing nonischemic HF. A central role of mROS in cardiac pathology is also supported by studies using the Szeto-Schiller peptide SS-31 59 (alternatively known as Bendavia, MTP-131, or Elamipretide). This peptide is thought to act by decreasing mROS production and preventing oxidation of cardiolipin in the mitochondrial membrane. 60, 61 It has been shown to be effective against myocardial infarction-induced ventricular remodeling 62 and improved function of Gq overexpressing or Ang II-treated mice. 63 Recently, Elamipretide was also shown to improve mitochondrial and cardiac function in canine ischemic HF induced by microembolization. 16 Several phase 2 clinical trials with Elamipretide in HF patients are underway 64 with a structure distinct from the targeted quinones. The inherent stability of the oxidized form of the nitroxyl moiety 65 of MitoTEMPO may be less toxic than other redox cycling antioxidant/oxidants 66 including mitoQ, 50 which could explain the unequivocal beneficial effects observed in the present study. In a mouse model of cardiomyopathy induced by cardiac-specific overexpression of angiotensin-converting enzyme, MitoTEMPO was shown to prevent ventricular arrhythmias and to mitigate mitochondrial dysfunction, but its untargeted form, TEMPOL, or other antioxidants (the NO synthase inhibitor L-NIO, precursor of tetrahydrobiopterin sepiapterin, apocynin, xanthine oxidase inhibitor allopurinol) did not. 9 MitoTEMPO was also shown to attenuate cardiomyopathy secondary to diabetes mellitus in db/ db 67 or high-fat fed C57BL/6J 68 mice and prevented the oxidation of calmodulin-dependent kinase II in a streptozotocintreated diabetic mice. 69 Although many interventions have been shown to inhibit the progression of HF, the demonstration in the present study that MitoTEMPO can rescue contractile function of failing hearts has therapeutic relevance. Moreover, the efficiency of MitoTEMPO to suppress arrhythmias (premature ventricular complexes and reentrant tachyarrhythmias) in the guinea pig model is likely to be relevant to humans, given the similar role of the rapid (IKr) and slow components (IKs) of the delayed rectifier K + current in cardiac repolarization, as well as the long cellular action potential plateau morphology that contributes to the prolonged QT interval of human HF. 70 Notably, MitoTEMPO withdrawal resulted in a manifest decline in contractile function without a return of SCD incidence, indicating that the pathophysiological regulation of myofilament responses may be isolated from the electrophysiological abnormalities. Further detailed investigation of this differential response is warranted to identify which mROS-dependent processes are involved in contractile versus electrical dysfunction in HF.
NOX also contributed to higher basal ROS in the ACi model, as evidenced by the partial inhibition of both mROS and cROS by apocynin or the GP91-ds-tat inhibitor of NOX2. These findings also indicate a hormone insensitive NOX component that is responsible for the receptor-independent basal NOX activity. Notably, MitoTEMPO was much more effective than the untargeted TEMPOL at preventing energy demand-related oxidative stress, whereas NOX inhibition was more effective at eliminating cROS increases induced by Ang II receptor stimulation.
In this study, proteome analysis yielded key insights into the pathways and causal networks triggered by mROS during cardiac decompensation. Importantly, the canonical pathways linked to HF in our previous multi-omic study of the ACi model 21 were among those significantly impacted by MitoTEMPO treatment. By inference, pathway z scores (Online Data Supplement; Tab 7) indicate that, during HF, ROS positively influence cytoskeletal remodeling (Rho GTPases, Integrin Signaling, Actin Cytoskeletal Remodeling), stress signals (ERK/MAPK), and inflammation (NF-κB Activation), while negatively influencing mitochondrial/metabolic pathways (LXR/RXR Activation, PPARα/RXRα Activation, PTEN signaling), antioxidant (Antioxidant Action of Vitamin C), and cAMP signaling (Protein Kinase A Signaling, Cardiac β-adrenergic Signaling). On the basis of the present results and our prior work, we suggest a working hypothesis whereby mROS disrupts the nuclear integration of cytoplasmic signals (eg, Ca 2+ , energy state, second messengers) to negatively impact the inherent ability of the myocyte to adapt to changing conditions and demands (schema in Figure 7 ). This provides a framework for further exploration of the causal chain of events linked to oxidative stress in HF.
MAP kinase pathways are known to be activated by ROS, so we further confirmed altered MAPK signaling in the ACi model in multiple ways: (1) significant MAPK activation was inferred from the subset of proteins altered in the expression proteome of the failing heart that were prevented by MitoTEMPO treatment, (2) MAPK was identified as a causal network regulator in the proteome alterations in HF that were prevented by MitoTEMPO, and (3) MAPK target phosphorylation sites were increased in end-stage HF, as detected by a MAPK phosphosite-directed antibody specific against proline-directed Ser phosphorylation. The role of stress-activated kinase pathways in cardiac hypertrophy and failure has been well studied using genetically engineered mice, but the net effect of MAP kinase inhibition on outcomes is difficult to predict, specific to the targeted subfamily, and thus far, unproven as a clinical intervention. 71 Double knockout of Erk1 and Erk2 results in eccentric cardiomyocyte growth, although activation of the Erk pathway by Mek1 overexpression promotes concentric hypertrophy 72 ; however, suppression of Erk signaling did not diminish the hypertrophic response to pressure overload in the same study. Increased activation of MAPK signaling by knockout of the dual specificity phosphatase DUSP6 increased hypertrophic cardiac growth throughout the lifetime of the mouse and protected against cardiac decompensation after myocardial infarction or pressure overload, 73 in keeping with the protective antiapoptotic effect of Erk1/2 noted in other studies. 74, 75 Enhanced cardiac hypertrophy and myopathy in response to pressure overload, Ang II infusion, or isoproterenol treatment was reported with dominant negative inhibition of p38 MAP kinase signaling, through a calcineurin-dependent mechanism, 76 whereas in normal myocytes, the p38 pathway was shown to be a negative regulator of excitation-contraction coupling through modulation of phosphatase activity.
77 Ask1 (apoptosis signal-regulating kinase 1) is potentially the most direct connection between cellular ROS and MAPK activation. An upstream activator of p38 MAP kinase and JNK, Ask1 activity is held in check by interaction with reduced thioredoxin. Transgenic overexpression of Ask1 did not affect the hypertrophic response to pressure overload or isoproterenol treatment but promoted apoptotic cell death and cardiomyopathy. 78 This effect was associated with JNK1/2, but not p38 MAP kinase, activation. Ask1 knockout was reported to inhibit ventricular hypertrophy after pressure overload or myocardial infarction while decreasing markers of apoptotic cell death. 79 The present results establishing a relationship between mROS and MAP kinase activation bear further scrutiny in follow-up studies to define which downstream actions of mROS involve specific MAP kinases and whether selective subproteomes within the cell respond differentially.
For example, it will be interesting to determine if the ROSdependent pathways modifying ion channels/excitability are the same as those impacting the observed chronic metabolic gene/protein remodeling.
In summary, this study highlights mROS as a major upstream factor driving both acute electrophysiological instability (leading to SCD) and chronic proteome remodeling (protein expression and phosphorylation) during cardiac decompensation. Detailed analysis of the mROS-dependent contribution to HF suggests that ROS-dependent signal transduction pathways, probably in the MAP kinase family, interrupt the coupling of cytosolic signals to the metabolic, antioxidant, and ion transport subproteomes as HF develops. The broad and significant impact of mROS scavenging to prevent or reverse the HF/SCD phenotype provides a tool to identify other control nodes for therapeutic intervention and warrants further testing to establish clinical use.
